Inactive Instrument

Tauriga Sciences, Inc.

TAUG

US87669X2053

Pharmaceuticals

Delayed OTC Markets Other stock markets 15:14:36 03/05/2024 BST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2022	Tauriga Sciences Inc. Receives its 10,000th E-Commerce Order	CI
2022	Tauriga Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	CI

Tauriga Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2021

June 29, 2021 at 10:26 pm

Tauriga Sciences, Inc. announced earnings results for the full year ended March 31, 2021. For the full year, the company announced total revenue was USD 285,319 compared to USD 234,389 a year ago. Operating loss was USD 3.389 million compared to USD 2.039 million a year ago. Net loss was USD 3.626 million compared to USD 3.033 million a year ago. Basic loss per share from continuing operations was USD 0.019 compared to USD 0.037 a year ago.

Latest news about Tauriga Sciences, Inc.

Tauriga Sciences Inc. Receives its 10,000th E-Commerce Order	25/03/22	CI
Tauriga Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	16/02/22	CI
Tauriga Sciences Inc. Receives its 9,000th E-Commerce Order	21/01/22	CI
Tauriga Sciences Inc. Receives Product Endorsement from the State of Alaska	21/12/21	CI
Tauriga Sciences Inc. Formally Submits its Clinical Study Protocol to the Institutional Review Board	17/12/21	CI
Tauriga Sciences, Inc. Appoints Matthew A. Shaw as Member of its Corporate Advisory Board	01/12/21	CI
Tauriga Sciences, Inc. has Changed its Name to Sublingual Technologies Inc	22/11/21	CI
Tauriga Sciences, Inc. Confirms the Commercial Launch of Its New & Improved Tauri-Gummies? Product, Kosher Certified by Orthodox Union	16/11/21	CI
Tauriga Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	15/11/21	CI
Tauriga Sciences, Inc. to Proceed with the Production of Its Proprietary Kratom Infused Chewing Gum	02/11/21	CI
Tauriga Sciences Inc. Enters into Strategic Alliance with Psychedelic Water	19/10/21	CI
Tauriga Sciences Inc. Commences Development of Ashwagandha Infused Chewing Gum	15/10/21	CI
Tauriga Sciences Inc. Expands its Product Offerings of Delta 8 THC Infused Gummies	08/10/21	CI
Tauriga Sciences Inc. Commences Development of Kratom Extract Infused Chewing Gum	07/10/21	CI
Tauriga Sciences, Inc. Announces Resignation of David Wolitzky from the Board of Directors	22/09/21	CI
Tauriga Sciences Inc. Products Offerings Now Available on Amazon Prime	16/09/21	CI
Tauriga Sciences Inc. Completes Funding of the Study Protocol Phase of Its Recently Initiated Clinical Trial	13/09/21	CI
Tauriga Sciences Inc. Fully Repays its $135,000 Inventory Factoring Credit Facility	03/09/21	CI
Tauriga Sciences, Inc. Initiates Clinical Trial to Examine the Effects of Cannabidiol Doses on Pregnant Women with Diagnosis of Hyperemesis Gravidarum	31/08/21	CI
Tauriga Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2021	16/08/21	CI
Tauriga Sciences Inc. Announces the Arrival of Product Inventory for its Enhanced Tauri-Gum Product Line	03/08/21	CI
Tauriga Sciences Inc. Introduces Two Innovative Topical Products: CBD Infused Sunscreen Spray and Acai Fragrance Moisturizing Lip Balm	12/07/21	CI
Tauriga Sciences Inc. Introduces Two Innovative Topical Products: CBD Infused Sunscreen Spray and Acai Fragrance Moisturizing Lip Balm	12/07/21	CI
Tauriga Sciences Inc. Announces Availability of its Products for Sale on Amazon.com	09/07/21	CI
Tauriga Sciences, Inc. and Think BIG, LLC Confirm the Launch of Two Limited-Edition Frank White/Tauri-Gum Versions	09/07/21	CI

Chart Tauriga Sciences, Inc.

Duration

Period

More charts

Company Profile

Tauriga Sciences, Inc. is a science, technology and consumer products company. The Company operates through its subsidiary, Tauriga Pharma Corp., which is focused on the development of a pharmaceutical product line that is synergistic with the Companyâs primary Cannabidiol (CBD) product line. The Company operates through two segments. The first division consists of all retail, wholesale and e-commerce product sales of CBD/CBG Tauri-Gum, Tauri-Gummies, and other CBD/CBG products. The second segment is the research and development division, which consists of liabilities and results from any activity relative to the progress in the development of the Companyâs Food and Drug Administration (FDA) and Investigational New Drug (IND) application for Phase II Trial of its proposed pharmaceutical-grade version of Tauri-Gum. It also developed an immune booster version of Tauri-Gum chewing gum. This product contains 60 milligrams (mg) of Vitamin C and 10mg of Elemental Zinc per piece.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals